{"DataElement":{"publicId":"5918370","version":"1","preferredName":"Gleason Score Grading System Group Category","preferredDefinition":"Defined characteristics based on the Gleason grading system for prostatic carcinoma that distills grade groups of prostate cancer down to the lowest number of grades, each with a unique prognosis.","longName":"GLSNSCR_GD_SYS_GP_CAT","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"5918362","version":"1","preferredName":"Gleason Score for Prostate Cancer Gleason Grading System Group","preferredDefinition":"A system of grading prostate cancer tissue based on how it looks under a microscope. Gleason scores range from 2 to 10 and indicate how likely it is that a tumor will spread. A low Gleason score means the cancer tissue is similar to normal prostate tissue and the tumor is less likely to spread; a high Gleason score means the cancer tissue is very different from normal and the tumor is more likely to spread._A grading system for prostatic carcinoma based on the microscopic glandular architectural patterns of the malignant epithelial cells. Nuclear atypia is not evaluated. It defines five patterns or grades which reflect decreasing differentiation._Any number of entities (members) considered as a unit.","longName":"2547908v1.0:5918360v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2547908","version":"1","preferredName":"Gleason Score for Prostate Cancer","preferredDefinition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","longName":"C28084","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score for Prostate Cancer","conceptCode":"C28084","definition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"23681B08-081C-19C0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-11-29","modifiedBy":"SBREXT","dateModified":"2017-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5918360","version":"1","preferredName":"Gleason Grading System Group","preferredDefinition":"A grading system for prostatic carcinoma based on the microscopic glandular architectural patterns of the malignant epithelial cells. Nuclear atypia is not evaluated. It defines five patterns or grades which reflect decreasing differentiation.:Any number of entities (members) considered as a unit.","longName":"C28107:C43359","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Grading System","conceptCode":"C28107","definition":"A grading system for prostatic carcinoma based on the microscopic glandular architectural patterns of the malignant epithelial cells. Nuclear atypia is not evaluated. It defines five patterns or grades which reflect decreasing differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Group","conceptCode":"C43359","definition":"Any number of entities (members) considered as a unit.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56411660-5C3E-1E52-E053-F662850AFF5E","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"56411660-5C4F-1E52-E053-F662850AFF5E","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"KNABLEJ","dateModified":"2018-11-28","changeDescription":"11/28/18 jk released per MCL review.  8/8/17 tt  New DEC per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5918364","version":"1","preferredName":"Gleason Score Group Category","preferredDefinition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable._Any number of entities (members) considered as a unit._A grouping of items based on some commonality or by user defined characteristics.","longName":"5918364v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"2","valueDescription":"Grade Group II","ValueMeaning":{"publicId":"6051013","version":"1","preferredName":"Grade Group II","longName":"6051013","preferredDefinition":"Predominantly well-formed glands with lesser component of poorly-formed/fused/cribriform glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Grade Group 2","conceptCode":"C137993","definition":"Gleason grade defined by Gleason score 3+4=7. (ISUP, 2014)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6296EA4E-E8B8-4ECB-E053-F662850A078F","latestVersionIndicator":"Yes","beginDate":"2018-01-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"629B1997-5E1A-3164-E053-F662850AF3BD","beginDate":"2017-08-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-01-12","modifiedBy":"ONEDATA","dateModified":"2018-01-12","deletedIndicator":"No"},{"value":"3","valueDescription":"Grade Group III","ValueMeaning":{"publicId":"6051226","version":"1","preferredName":"Grade Group III","longName":"6051226","preferredDefinition":"Predominantly poorly formed/fused/cribriform glands with lesser component of well-formed glands. For cases with greater than 95% poorly formed/fused/cribriform glands or lack of glands on a core or at radical prostatectomy, the component of less than 5% well-formed glands is not factored into the grade.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Grade Group 3","conceptCode":"C137994","definition":"Gleason grade defined by Gleason score 4+3=7. (ISUP, 2014)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"629B0D42-3D18-5846-E053-F662850A0B42","latestVersionIndicator":"Yes","beginDate":"2018-01-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"629B1997-5E2E-3164-E053-F662850AF3BD","beginDate":"2018-01-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-01-12","modifiedBy":"ONEDATA","dateModified":"2018-01-12","deletedIndicator":"No"},{"value":"1","valueDescription":"Grade Group I","ValueMeaning":{"publicId":"6051222","version":"1","preferredName":"Grade Group I","longName":"6051222","preferredDefinition":"Only individual discrete well-formed glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Grade Group 1","conceptCode":"C137992","definition":"Gleason grade defined by Gleason score less than or equal to 6. (ISUP, 2014)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"629AC085-ACD4-57D5-E053-F662850A8871","latestVersionIndicator":"Yes","beginDate":"2018-01-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"629B0D42-3D45-5846-E053-F662850A0B42","beginDate":"2018-01-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-01-12","modifiedBy":"ONEDATA","dateModified":"2018-01-12","deletedIndicator":"No"},{"value":"4","valueDescription":"Grade Group IV","ValueMeaning":{"publicId":"6051227","version":"1","preferredName":"Grade Group IV","longName":"6051227","preferredDefinition":"Only poorly-formed/fused/cribriform glands or Predominantly well-formed glands and lesser component lacking glands or Predominantly lacking glands and lesser component of well-formed gland. Poorly-formed/fused/cribriform glands can be a more minor component.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Grade Group 4","conceptCode":"C137995","definition":"Gleason grade defined by Gleason score 4+4=8, Gleason score 3+5=8, or Gleason score 5+3=8. (ISUP, 2014)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"629B0D42-3D51-5846-E053-F662850A0B42","latestVersionIndicator":"Yes","beginDate":"2018-01-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"629B0D42-3D6A-5846-E053-F662850A0B42","beginDate":"2017-08-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-01-12","modifiedBy":"ONEDATA","dateModified":"2018-01-12","deletedIndicator":"No"},{"value":"5","valueDescription":"Grade Group V","ValueMeaning":{"publicId":"6051228","version":"1","preferredName":"Grade Group V","longName":"6051228","preferredDefinition":"Lacks gland formation (or with necrosis) with or without poorly formed/fused/cribriform glands. For cases with greater than 95% poorly formed/fused/cribriform glands or lack of glands on a core or at RP, the component of less than 5% well-formed glands is not factored into the grade.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Grade Group 5","conceptCode":"C137996","definition":"Gleason grade defined by Gleason score 9-10. (ISUP, 2014)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"629B0D42-3D76-5846-E053-F662850A0B42","latestVersionIndicator":"Yes","beginDate":"2018-01-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"629B0D42-3D8F-5846-E053-F662850A0B42","beginDate":"2017-08-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-01-12","modifiedBy":"ONEDATA","dateModified":"2018-01-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5918363","version":"1","preferredName":"Gleason Score for Prostate Cancer Group Category","preferredDefinition":"A system of grading prostate cancer tissue based on how it looks under a microscope. Gleason scores range from 2 to 10 and indicate how likely it is that a tumor will spread. A low Gleason score means the cancer tissue is similar to normal prostate tissue and the tumor is less likely to spread; a high Gleason score means the cancer tissue is very different from normal and the tumor is more likely to spread.:Any number of entities (members) considered as a unit.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C28084:C43359:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score for Prostate Cancer","conceptCode":"C28084","definition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Group","conceptCode":"C43359","definition":"Any number of entities (members) considered as a unit.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5640E089-C5BF-01F2-E053-F662850AB269","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"5640E089-C5D0-01F2-E053-F662850AB269","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"KNABLEJ","dateModified":"2018-11-28","changeDescription":"11/28/18 jk released per MCL review. 8/8/17 tt New VD per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5506113","version":"1","longName":"Prostate","context":"MCL","ClassificationSchemeItems":[{"publicId":"5855639","version":"1","longName":"Prostate Core","context":"MCL"}]},{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"5915896","version":"1","longName":"Gross Pathology","context":"NCI Standards"}]},{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"5635376","version":"1","longName":"Prostate","context":"OCCPR"},{"publicId":"6779561","version":"1","longName":"PRAD Baseline","context":"OCCPR"},{"publicId":"6779562","version":"1","longName":"PRAD Local Pathology","context":"OCCPR"},{"publicId":"6779563","version":"1","longName":"PRAD Pathology Review","context":"OCCPR"}]}],"AlternateNames":[{"name":"MCL","type":"USED_BY","context":"MCL"},{"name":"OCCPR","type":"USED_BY","context":"OCCPR"},{"name":"MI_MIORRES_GRDGRP","type":"OID, CCTG","context":"CCTG"}],"ReferenceDocuments":[{"name":"Gleason grade group","type":"Preferred Question Text","description":"Gleason grade group","url":null,"context":"NCI Standards"},{"name":"MCL-PCA","type":"Alternate Question Text","description":"Grade group","url":null,"context":"MCL"},{"name":"CPTAC-PRAD-1","type":"Alternate Question Text","description":"Grade Group","url":null,"context":"OCCPR"},{"name":"DCP-Text-1","type":"Alternate Question Text","description":"Highest Gleason Grade Group","url":null,"context":"DCP"}],"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"5641CA9D-B718-2F55-E053-F662850A1B31","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"MMADDINENI","dateModified":"2024-01-09","changeDescription":"7/12/19 tt corrected typo in definition. 11/28/18 jk released per MCL review; added MCL CSI.  8/8/17 tt Draft New CDE per Round 5 finalization task.","administrativeNotes":"11/16/23 Added alt OID for CCTG ticket number CADSR0003085 cjl","unresolvedIssues":null,"deletedIndicator":"No"}}